Carisma Therapeutics Inc
NASDAQ:CARM

Watchlist Manager
Carisma Therapeutics Inc Logo
Carisma Therapeutics Inc
NASDAQ:CARM
Watchlist
Price: 0.0411 USD -6.59% Market Closed
Market Cap: 1.7m USD

Carisma Therapeutics Inc
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Carisma Therapeutics Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Carisma Therapeutics Inc
NASDAQ:CARM
Accrued Liabilities
$3.1m
CAGR 3-Years
-53%
CAGR 5-Years
-8%
CAGR 10-Years
18%
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$3B
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
20%
No Stocks Found

Carisma Therapeutics Inc
Glance View

Market Cap
1.7m USD
Industry
Biotechnology

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2014-02-06. The firm is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The firm's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.

CARM Intrinsic Value
Not Available

See Also

What is Carisma Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
3.1m USD

Based on the financial report for Jun 30, 2025, Carisma Therapeutics Inc's Accrued Liabilities amounts to 3.1m USD.

What is Carisma Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
18%

Over the last year, the Accrued Liabilities growth was -70%. The average annual Accrued Liabilities growth rates for Carisma Therapeutics Inc have been -53% over the past three years , -8% over the past five years , and 18% over the past ten years .

Back to Top